Low-Dose Amikacin as Alternative Treatment for Multidrug-Resistant Tuberculosis

resisttb
Jun 24, 2021
1 min read

Low-dose amikacin with appropriate dose adjustment based on adequate monitoring demonstrated limited toxicity with positive outcomes as a treatment option for multidrug-resistant tuberculosis (MDR-TB), according to the findings of a retrospective cohort study published in BMC Infectious Diseases. Read here

Recent Posts

See All

International Course on the Clinical and Programmatic Management of DRTB

In person in Taipei in October 2025, by Prof Chen-Yuan Chiang. This course is essential for staff from National TB Programmes in charge...

USAid cuts could create untreatable TB bug ‘resistant to everything we have’

The Stop TB Partnership has raised alarms for the potential for new TB mutations associated with interruptions in care. The COVID...

World Health Organization warns of possible tuberculosis surge because of USAID cuts

A recent statement from the WHO warned of a spike in tuberculosis as a result of the shuttering of USAID. This trend can already be seen...

Comments